Terms: = Lung cancer AND MYC, c-Myc, 4609, ENSG00000136997
1846 results:
1. The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability.
Abad E; Sandoz J; Romero G; Zadra I; Urgel-Solas J; Borredat P; Kourtis S; Ortet L; Martínez CM; Weghorn D; Sdelci S; Janic A
J Exp Clin Cancer Res; 2024 Apr; 43(1):127. PubMed ID: 38685100
[TBL] [Abstract] [Full Text] [Related]
2. Transitioning to a Personalized Approach in Molecularly Subtyped Small-Cell lung cancer (SCLC).
Grenda A; Krawczyk P; Obara A; Gajek Ł; Łomża-Łaba A; Milanowski J
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673793
[TBL] [Abstract] [Full Text] [Related]
3. Elucidating the role of EPPK1 in lung adenocarcinoma development.
Arimura K; Kammer M; Rahman SMJ; Sheau-Chiann C; Zhao S; Heidi C; Eisenberg R; Zou Y; Antic S; Richmond B; Tagaya E; Grogan E; Massion P; Maldonado F
BMC Cancer; 2024 Apr; 24(1):441. PubMed ID: 38594604
[TBL] [Abstract] [Full Text] [Related]
4. Characterization of cell cycle, inflammation, and oxidative stress signaling role in non-communicable diseases: Insights into genetic variants, microRNAs and pathways.
D'Antona S; Porro D; Gallivanone F; Bertoli G
Comput Biol Med; 2024 May; 174():108346. PubMed ID: 38581999
[TBL] [Abstract] [Full Text] [Related]
5. Development, synthesis and validation of improved c-myc/Max inhibitors.
Yıldırım S; Kocabaş F; Mermer A
J Cell Mol Med; 2024 Apr; 28(8):e18272. PubMed ID: 38568057
[TBL] [Abstract] [Full Text] [Related]
6. NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade.
Ma Z; Ma Y; Feng J; Xu Z; Cheng C; Qin J; Li S; Jiang J; Kong R
Toxicol Appl Pharmacol; 2024 Apr; 485():116915. PubMed ID: 38537875
[TBL] [Abstract] [Full Text] [Related]
7. Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer.
Zhang YZ; Lai HL; Huang C; Jiang ZB; Yan HX; Wang XR; Xie C; Huang JM; Ren WK; Li JX; Zhai ZR; Yao XJ; Wu QB; Leung EL
Phytomedicine; 2024 Jun; 128():155431. PubMed ID: 38537440
[TBL] [Abstract] [Full Text] [Related]
8. Polyphyllin I enhances tumor necrosis factor-related apoptosis-inducing ligand-induced inhibition of human osteosarcoma cell growth downregulating the Wnt/β-catenin pathway.
Junli C; Fulai Z; Xingyuan S; Xiaoping MA; Peng Z; Chujie Z; Binhao S; Wenchao GU; Yongjun W; Yanping Y
J Tradit Chin Med; 2024 Apr; 44(2):251-259. PubMed ID: 38504531
[TBL] [Abstract] [Full Text] [Related]
9. Patient-derived tumoroid models of pulmonary large-cell neuroendocrine carcinoma: a promising tool for personalized medicine and developing novel therapeutic strategies.
Yokota E; Iwai M; Yukawa T; Naomoto Y; Haisa M; Monobe Y; Takigawa N; Fukazawa T; Yamatsuji T
Cancer Lett; 2024 Apr; 588():216816. PubMed ID: 38499265
[TBL] [Abstract] [Full Text] [Related]
10. GATA6 inhibits the biological function of non-small cell lung cancer by modulating glucose metabolism.
Ju W; Lin L; Zhang Q; Lv X; Teng S; Hong Y; Shao Z; Na H; Yu S
J Cancer Res Clin Oncol; 2024 Mar; 150(3):126. PubMed ID: 38483616
[TBL] [Abstract] [Full Text] [Related]
11. Evolutionary trajectories of small cell lung cancer under therapy.
George J; Maas L; Abedpour N; Cartolano M; Kaiser L; Fischer RN; Scheel AH; Weber JP; Hellmich M; Bosco G; Volz C; Mueller C; Dahmen I; John F; Alves CP; Werr L; Panse JP; Kirschner M; Engel-Riedel W; Jürgens J; Stoelben E; Brockmann M; Grau S; Sebastian M; Stratmann JA; Kern J; Hummel HD; Hegedüs B; Schuler M; Plönes T; Aigner C; Elter T; Toepelt K; Ko YD; Kurz S; Grohé C; Serke M; Höpker K; Hagmeyer L; Doerr F; Hekmath K; Strapatsas J; Kambartel KO; Chakupurakal G; Busch A; Bauernfeind FG; Griesinger F; Luers A; Dirks W; Wiewrodt R; Luecke A; Rodermann E; Diel A; Hagen V; Severin K; Ullrich RT; Reinhardt HC; Quaas A; Bogus M; Courts C; Nürnberg P; Becker K; Achter V; Büttner R; Wolf J; Peifer M; Thomas RK
Nature; 2024 Mar; 627(8005):880-889. PubMed ID: 38480884
[TBL] [Abstract] [Full Text] [Related]
12. Arenobufagin inhibits lung metastasis of colorectal cancer by targeting c-myc/Nrf2 axis.
Wang M; Hu S; Yang J; Yuan L; Han L; Liang F; Zhang F; Zhao H; Liu Y; Gao N
Phytomedicine; 2024 May; 127():155391. PubMed ID: 38452690
[TBL] [Abstract] [Full Text] [Related]
13. NSUN2 promotes lung adenocarcinoma progression through stabilizing PIK3R2 mRNA in an m
Du X; Cheng C; Yang Y; Fan B; Wang P; Xia H; Ni X; Liu Q; Lu L; Wei L
Mol Carcinog; 2024 May; 63(5):962-976. PubMed ID: 38411298
[TBL] [Abstract] [Full Text] [Related]
14. Acquired Cross-Resistance in Small Cell lung cancer due to Extrachromosomal DNA Amplification of myc Paralogs.
Pal Choudhuri S; Girard L; Lim JYS; Wise JF; Freitas B; Yang D; Wong E; Hamilton S; Chien VD; Kim YJ; Gilbreath C; Zhong J; Phat S; Myers DT; Christensen CL; Mazloom-Farsibaf H; Stanzione M; Wong KK; Hung YP; Farago AF; Meador CB; Dyson NJ; Lawrence MS; Wu S; Drapkin BJ
Cancer Discov; 2024 May; 14(5):804-827. PubMed ID: 38386926
[TBL] [Abstract] [Full Text] [Related]
15. C-myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer.
Lang C; Megyesfalvi Z; Lantos A; Oberndorfer F; Hoda MA; Solta A; Ferencz B; Fillinger J; Solyom-Tisza A; Querner AS; Egger F; Boettiger K; Klikovits T; Timelthaler G; Renyi-Vamos F; Aigner C; Hoetzenecker K; Laszlo V; Schelch K; Dome B
World J Surg Oncol; 2024 Feb; 22(1):57. PubMed ID: 38369463
[TBL] [Abstract] [Full Text] [Related]
16. Influence of
Naqash AR; Floudas CS; Aber E; Maoz A; Nassar AH; Adib E; Choucair K; Xiu J; Baca Y; Ricciuti B; Alessi JV; Awad MM; Kim C; Judd J; Raez LE; Lopes G; Nieva JJ; Borghaei H; Takebe N; Ma PC; Halmos B; Kwiatkowski DJ; Liu SV; Mamdani H
JCO Precis Oncol; 2024 Feb; 8():e2300371. PubMed ID: 38330261
[TBL] [Abstract] [Full Text] [Related]
17. Lineage-specific intolerance to oncogenic drivers restricts histological transformation.
Gardner EE; Earlie EM; Li K; Thomas J; Hubisz MJ; Stein BD; Zhang C; Cantley LC; Laughney AM; Varmus H
Science; 2024 Feb; 383(6683):eadj1415. PubMed ID: 38330136
[TBL] [Abstract] [Full Text] [Related]
18. Dynamic phenotypic reprogramming and chemoresistance induced by lung fibroblasts in small cell lung cancer.
Lu Y; Li H; Zhao P; Tian L; Liu Y; Sun X; Cheng Y
Sci Rep; 2024 Feb; 14(1):2884. PubMed ID: 38311608
[TBL] [Abstract] [Full Text] [Related]
19. EZH2/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4/ERK/c-myc signaling axis.
Zhang Q; Shi Y; Liu S; Yang W; Chen H; Guo N; Sun W; Zhao Y; Ren Y; Ren Y; Jia L; Yang J; Yun Y; Chen G; Wang L; Wu C
Cell Rep; 2024 Feb; 43(2):113714. PubMed ID: 38306271
[TBL] [Abstract] [Full Text] [Related]
20. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
Liu S; Chai T; Garcia-Marques F; Yin Q; Hsu EC; Shen M; Shaw Toland AM; Bermudez A; Hartono AB; Massey CF; Lee CS; Zheng L; Baron M; Denning CJ; Aslan M; Nguyen HM; Nolley R; Zoubeidi A; Das M; Kunder CA; Howitt BE; Soh HT; Weissman IL; Liss MA; Chin AI; Brooks JD; Corey E; Pitteri SJ; Huang J; Stoyanova T
Cell Rep Med; 2024 Feb; 5(2):101381. PubMed ID: 38244540
[TBL] [Abstract] [Full Text] [Related]
[Next]
